Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Shares Issued (2016 - 2024)

ImmunityBio (IBRX) has disclosed Shares Issued for 10 consecutive years, with $15.6 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Issued changed N/A to $15.6 million in Q3 2024 year-over-year; TTM through Jun 2025 was $15.6 million, a 76.65% decrease, with the full-year FY2024 number at $73.3 million, changed N/A from a year prior.
  • Shares Issued was $15.6 million for Q3 2024 at ImmunityBio, down from $52.8 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $132.5 million in Q3 2021 to a low of -$131.5 million in Q4 2021.
  • A 4-year average of $8.8 million and a median of $2.2 million in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: tumbled 98.86% in 2020, then skyrocketed 33029.0% in 2021.
  • ImmunityBio's Shares Issued stood at $400000.0 in 2020, then tumbled by 32971.75% to -$131.5 million in 2021, then surged by 99.94% to -$74000.0 in 2022, then soared by 21204.05% to $15.6 million in 2024.
  • Per Business Quant, the three most recent readings for IBRX's Shares Issued are $15.6 million (Q3 2024), $52.8 million (Q2 2024), and $14.1 million (Q1 2024).